Merck & Co., Inc. (MRK)
Merck lowers profit outlook due to expected $200M tariff hit
Merck & Co Inc (NYSE:MRK, ETR:6MK) has lowered its full-year earnings forecast due to an expected $200 million hit from global tariffs, notably levies between the US and China. The company now expects 2025 earnings per share (EPS) in the range of $8.82 to $8.97, down from its prior forecast of $8.88 to $9.03.
2 Blue-Chip Stocks Brushing Off Earnings Beats
Pharmaceutical giant Merck & Co Inc (NYSE:MRK) has reversed its premarket lead, down 2% at $77.20 at last glance.
Merck (MRK) Q1 Earnings and Revenues Top Estimates
Merck (MRK) came out with quarterly earnings of $2.22 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $2.07 per share a year ago.
Merck Cuts 2025 View on Tariffs, Charges
Merck's first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 adjusted earnings projection, partly to account for recently imposed tariffs.
Merck Q1 Earnings Coming Up: Should You Buy the Stock Now?
When Merck reports first-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, Keytruda.
Merck: Now A Single-Digit P/E With Double-Digit EPS Growth, Technical Support
The Health Care sector outperformed the S&P 500 in 2025, with XLV returning -1.5% YTD compared to SPY's -10% decline. Despite mixed performance, Merck's stock has dropped 37% since mid-2024, but I maintain a buy rating due to long-term support and potential growth drivers. Merck's Q4 results beat expectations, but concerns over Gardasil and Keytruda's patent expirations have weighed on the stock.
Merck & Co.: Pipeline Resilience To Unlock Value
I initiate coverage on Merck & Co., Inc. with a Strong Buy rating and a $139 price target, driven by resilient execution and robust product depth. Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. New product launches like WINREVAIR are exceeding expectations and offsetting pipeline risk.
Ahead of Merck (MRK) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Merck (MRK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
Merck (MRK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Merck (MRK) Stock Drops Despite Market Gains: Important Facts to Note
The latest trading day saw Merck (MRK) settling at $79.17, representing a -0.01% change from its previous close.
Wall Street Analysts Think Merck (MRK) Is a Good Investment: Is It?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
